Skip to main content

Articles

Page 1 of 6

  1. Glioblastoma (GBM), is the most fatal form of brain cancer, with a high tendency for recurrence despite combined treatments including surgery, radiotherapy, and chemotherapy with temozolomide. The C-X-C chemok...

    Authors: Anthony Waked, Melissa Crabbé, Virginie Neirinckx, Sunay Rodriguez Pérez, Jasmien Wellens, Bernard Rogister, M. Abderrafi Benotmane and Koen Vermeulen
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:52
  2. 4-[18F]fluorobenzyl-triphenylphosphonium ([18F]FBnTP) is a lipophilic cation PET tracer. The cellular uptake of [18F]FBnTP is correlated with oxidative phosphorylation by mitochondria, which has been associated w...

    Authors: Mai Lin, Cong-Dat Pham, Robert T. Ta and H. Charles Manning
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:51
  3. In the last decade the development of new PSMA-ligand based radiopharmaceuticals for the imaging and therapy of prostate cancer has been a highly active and important area of research. The most promising deriv...

    Authors: Marco Nicola Iannone, Silvia Valtorta, Stefano Stucchi, Stefano Altomonte, Elia Anna Turolla, Elisa Vino, Paolo Rainone, Valentina Zecca, Alessia Lo Dico, Marco Maspero, Mariangela Figini, Matteo Bellone, Samuele Ciceri, Diego Colombo, Clizia Chinello, Lisa Pagani…
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:50
  4. Infection remains a major cause of morbidity and mortality, regardless of advances in antimicrobial therapy and improved knowledge of microorganisms. With the major global threat posed by antimicrobial resista...

    Authors: Maryke Kahts, Beverley Summers, Aadil Gutta, Wilfrid Pilloy and Thomas Ebenhan
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:49
  5. Prostate cancer is a common cancer among men worldwide that has a very poor prognosis, especially when it progresses to metastatic castration-resistant prostate cancer (mCRPC). Therefore, novel therapeutic age...

    Authors: Hiroyuki Suzuki, Kento Kannaka, Mizuki Hirayama, Tomoki Yamashita, Yuta Kaizuka, Ryota Kobayashi, Takahiro Yasuda, Kazuhiro Takahashi and Tomoya Uehara
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:48
  6. Trans-cyclooctenes (TCOs) are highly strained alkenes with remarkable reactivity towards tetrazines (Tzs) in inverse electron-demand Diels–Alder reactions. Since their discovery as bioorthogonal reaction partners...

    Authors: Karuna Adhikari, Maarten Vanermen, Gustavo Da Silva, Tim Van den Wyngaert, Koen Augustyns and Filipe Elvas
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:47
  7. Signal transducer and activator of transcription 3 (STAT3) is a protein that regulates cell proliferation and differentiation, and it is attracting attention as a new index for evaluating cancer pathophysiolog...

    Authors: Anna Miyazaki, Yasukazu Kanai, Keita Wakamori, Serina Mizuguchi, Mikiya Futatsugi, Fuko Hirano, Naoya Kondo and Takashi Temma
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:46
  8. Histone deacetylase 6 (HDAC6) is an emerging target for the treatment and diagnosis of proteinopathies. [18F]FSW-100 was recently developed as a promising brain-penetrating radioligand for HDAC6 PET imaging and t...

    Authors: Tetsuro Tago and Jun Toyohara
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:45
  9. Integrating radioactive and optical imaging techniques can facilitate the prognosis and surgical guidance for cancer patients. Using a single dual-labeled tracer ensures consistency in both imaging modalities....

    Authors: Dylan Chapeau, Savanne Beekman, Maryana Handula, Erika Murce, Corrina de Ridder, Debra Stuurman and Yann Seimbille
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:44
  10. A significant challenge in cancer therapy lies in eradicating hidden disseminated tumor cells. Within Nuclear Medicine, Targeted Alpha Therapy is a promising approach for cancer treatment tackling disseminated...

    Authors: Chiara Timperanza, Holger Jensen, Ellinor Hansson, Tom Bäck, Sture Lindegren and Emma Aneheim
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:43
  11. The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development.

    Authors: Jun Toyohara, Danielle Vugts, Oliver C. Kiss, Sergio Todde, Xiang-Guo Li, Zhibo Liu, Zhi Yang, Nic Gillings, Emiliano Cazzola, Wiktor Szymanski, Nick van der Meulen, Raymond Reilly, Carlotta Taddei, Ralf Schirrmacher, Zijing Li, Yohannes Jorge Lagebo…
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:42
  12. Determination of the functional liver mass is important in a variety of clinical settings including liver surgery and transplantation. [99mTc]Tc-diethylenetriamine-pentaacetic acid galactosyl human serum albumin ...

    Authors: Maximilian A. Zierke, Christine Rangger, Kimia Samadikhah, Marlene Panzer, Stefanie Dichtl, Nikolas Hörmann, Doris Wilflingseder, Andreas M. Schmid and Roland Haubner
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:41
  13. During the previous two decades, PET imaging of biopharmaceuticals radiolabeled with zirconium-89 has become a consistent tool in preclinical and clinical drug development and patient selection, primarily due ...

    Authors: Thomas Erik Wuensche, Serge Lyashchenko, Guus A. M. S. van Dongen and Danielle Vugts
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:40
  14. Automated [89Zr]Zr-radiolabeling processes have the potential to streamline the production of [89Zr]Zr-labelled PET imaging agents. Most radiolabeling protocols use [89Zr][Zr(ox)4]4− as the starting material and ...

    Authors: Asif Noor, Peter D. Roselt, Emily R. McGowan, Stan Poniger, Michael P. Wheatcroft and Paul S. Donnelly
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:39
  15. Positron emission tomography (PET) is a highly sensitive method that provides fine resolution images, useful in the field of clinical diagnostics. In this context, Zirconium-89 (89Zr)-based imaging agents have re...

    Authors: Valentina Albanese, Chiara Roccatello, Salvatore Pacifico, Remo Guerrini, Delia Preti, Silvia Gentili, Matteo Tegoni, Maurizio Remelli, Denise Bellotti, Jonathan Amico, Giancarlo Gorgoni and Emiliano Cazzola
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:38
  16. Radiation nanomedicines are nanoparticles labeled with radionuclides that emit α- or β-particles or Auger electrons for cancer treatment. We describe here our 15 years scientific journey studying locally-admin...

    Authors: Raymond M. Reilly, Constantine J. Georgiou, Madeline K. Brown and Zhongli Cai
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:37
  17. In recent years, fibroblast activating protein (FAP), a biomarker overexpressed by cancer-associated fibroblasts, has emerged as one of the most promising biomarkers in oncology. Similarly, FAP overexpression ...

    Authors: Alessandra Boschi, Luca Urso, Licia Uccelli, Petra Martini and Luca Filippi
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:36
  18. Parkinson's disease is a neurodegenerative disorder that is characterized by a degeneration of the dopaminergic system. Dopamine transporter (DAT) positron emission tomography (PET) imaging has emerged as a po...

    Authors: Mélodie Ferrat, Mohammad M. Moein, Carmen Cananau, Tetyana Tegnebratt, Paul Saliba, Fredrik Norman, Carsten Steiger, Klas Bratteby, Erik Samén, Kenneth Dahl and Thuy A. Tran
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:35
  19. 6-Bromo-7-[11C]methylpurine ([11C]BMP) is a radiotracer for positron emission tomography (PET) to measure multidrug resistance-associated protein 1 (MRP1) transport activity in different tissues. Previously repor...

    Authors: Severin Mairinger, Matthias Jackwerth, Ondřej Soukup, Matthias Blaickner, Clemens Decristoforo, Lukas Nics, Jens Pahnke, Marcus Hacker, Markus Zeitlinger and Oliver Langer
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:34
  20. The aim of this study was to prepare a novel 68Ga-labeled pH (low) insertion peptide (pHLIP)-like peptide, YJL-4, and determine its value for the early diagnosis of triple-negative breast cancer (TNBC) via in viv...

    Authors: YueHua Chen, ShuangShuang Song, YanQin Sun, FengYu Wu, GuangJie Yang, ZhenGuang Wang and MingMing Yu
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:33
  21. Megalin (LRP2 receptor) mediates the endocytosis of radiolabeled peptides into proximal tubular kidney cells, which may cause nephrotoxicity due to the accumulation of a radioactive tracer. The study aimed to ...

    Authors: Anna Durinova, Lucie Smutna, Pavel Barta, Rajamanikkam Kamaraj, Tomas Smutny, Bernhard Schmierer, Petr Pavek and Frantisek Trejtnar
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:32
  22. Steps have been taken by pharmaceutical companies to obtain marketing authorisation of PSMA ligands in the European Union. Since December 2022, Locametz® (PSMA-11, gozetotide) is licensed as kit for manual rad...

    Authors: Elke A. van Brandwijk, Else A. Aalbersberg, Arman S. Hosseini, Alwin D. R. Huitema and Jeroen J. M. A. Hendrikx
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:31
  23. Radionuclide molecular imaging can be used to visualize the expression levels of molecular targets. Affibody molecules, small and high affinity non-immunoglobulin scaffold-based proteins, have demonstrated pro...

    Authors: Maryam Oroujeni, Matilda Carlqvist, Eva Ryer, Anna Orlova, Vladimir Tolmachev and Fredrik Y. Frejd
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:30
  24. The alpha emitter astatine-211 (211At) is garnering attention as a novel targeted alpha therapy for patients with refractory thyroid cancer resistant to conventional therapy using beta emitter radioiodine (131I)....

    Authors: Sadahiro Naka, Kazuhiro Ooe, Yoshifumi Shirakami, Kenta Kurimoto, Toshihiro Sakai, Kazuhiro Takahashi, Atsushi Toyoshima, Yang Wang, Hiromitsu Haba, Hiroki Kato, Noriyuki Tomiyama and Tadashi Watabe
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:29
  25. (S)-[18F]FETrp is a promising PET radiotracer for imaging IDO1 activity, one of the main enzymes involved in the tryptophan metabolism that plays a key role in several diseases including cancers. To date, the rad...

    Authors: Aurélie Maisonial-Besset, David Kryza, Klaus Kopka, Sophie Levesque, Emmanuel Moreau, Barbara Wenzel and Jean-Michel Chezal
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:28
  26. Tau pathology plays a crucial role in neurodegeneration diseases including Alzheimer’s disease (AD) and non-AD diseases such as progressive supranuclear palsy. Tau positron emission tomography (PET) is an in-v...

    Authors: Kun-Ju Lin, Shao-Yi Huang, Kuo-Lun Huang, Chin-Chang Huang and Ing-Tsung Hsiao
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:27
  27. To investigate the capacity of 99mTc-labeled 1-thio-β-D-glucose (1-TG) and 5-thio-D-glucose (5-TG) to act as a marker for glucose consumption in tumor cells in vivo as well as to evaluate the biodistribution of 1...

    Authors: Fabian Muehlberg, Konrad Mohnike, Oliver S. Grosser, Maciej Pech, Juergen Goldschmidt, Karl-Heinz Smalla, Ricarda Seidensticker, Muzaffer Reha Ümütlü, Sinan Deniz, Jens Ricke, Ingo G. Steffen, Osman Öcal and Max Seidensticker
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:26
  28. The urgent demand for innovative theranostic strategies to combat bacterial resistance to antibiotics is evident, with substantial implications for global health. Rapid diagnosis of life-threatening infections...

    Authors: Jyotsna Bhatt Mitra, Saurav Chatterjee, Anuj Kumar, Elina Khatoon, Ashok Chandak, Sutapa Rakshit, Anupam Bandyopadhyay and Archana Mukherjee
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:25
  29. Production of [11C]CH4 from gas targets is notorious for weak performance with respect to yield, especially when using high beam currents. Post-target conversion of [11C]CO2 to [11C]CH4 is a widely used roundabou...

    Authors: Semi Helin, Johan Rajander, Jussi Aromaa, Eveliina Arponen, Jatta S. Helin and Olof Solin
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:24
  30. Both in clinical routine and in preclinical research, the established standard procedure for the final purification of radiometal-labeled peptide radiopharmaceuticals is cartridge-based reversed-phase (RP) sol...

    Authors: Sebastian Martin, Lennard Wendlinger, Alexandra Litvinenko, Radmila Faizova and Margret Schottelius
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:23
  31. The brain is a challenging target for antibody-based positron emission tomography (immunoPET) imaging due to the restricted access of antibody-based ligands through the blood–brain barrier (BBB). To overcome t...

    Authors: Eva Schlein, Johanna Rokka, Luke R. Odell, Sara Lopes van den Broek, Matthias M. Herth, Umberto M. Battisti, Stina Syvänen, Dag Sehlin and Jonas Eriksson
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:21
  32. Siderophores are small iron-binding molecules produced by microorganisms to facilitate iron acquisition from the environment. Radiolabelled siderophores offer a promising solution for infection imaging, as the...

    Authors: Kristyna Krasulova, Barbora Neuzilova, Katerina Dvorakova Bendova, Zbynek Novy, Miroslav Popper, Marian Hajduch and Milos Petrik
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:20
  33. Heat shock proteins (HSPs) are present throughout the brain. They function as molecular chaperones, meaning they help with the folding and unfolding of large protein complexes. These chaperones are vital in th...

    Authors: Takayuki Sakai, Aya Ogata, Hiroshi Ikenuma, Takashi Yamada, Saori Hattori, Junichiro Abe, Shinichi Imamura, Masanori Ichise, Mari Tada, Akiyoshi Kakita, Hiroko Koyama, Masaaki Suzuki, Takashi Kato, Kengo Ito and Yasuyuki Kimura
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:19
  34. Radiohybrid PSMA-targeted ligands (rhPSMA) have been introduced as a novel platform for theranostic applications. Among a variety of rhPSMA-ligands developed for radioligand therapy, two stereoisomers [177Lu]Lu-r...

    Authors: Alexander Wurzer, Francesco De Rose, Sebastian Fischer, Markus Schwaiger, Wolfgang Weber, Stephan Nekolla, Hans-Jürgen Wester, Matthias Eiber and Calogero D’Alessandria
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:18
  35. L-type amino acid transporter 1 (LAT1) is overexpressed in various cancers; therefore, radiohalogen-labeled amino acid derivatives targeting LAT1 have emerged as promising candidates for cancer radiotheranosti...

    Authors: Yuta Kaizuka, Hiroyuki Suzuki, Tadashi Watabe, Kazuhiro Ooe, Atsushi Toyoshima, Kazuhiro Takahashi, Koichi Sawada, Takashi Iimori, Yoshitada Masuda, Takashi Uno, Kento Kannaka and Tomoya Uehara
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:17
  36. Fatty acid binding protein 3 (FABP3) is a target with clinical relevance and the peptide ligand ACooP has been identified for FABP3 targeting. ACooP is a linear decapeptide containing a free amino and thiol gr...

    Authors: Pyry Dillemuth, Tuomas Karskela, Abiodun Ayo, Jesse Ponkamo, Jonne Kunnas, Johan Rajander, Olli Tynninen, Anne Roivainen, Pirjo Laakkonen, Anu J. Airaksinen and Xiang-Guo Li
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:16
  37. Recent advancements in positron emission tomograph (PET) using prostate specific membrane antigen (PSMA)-targeted radiopharmaceuticals have changed the standard of care for prostate cancer patients by providin...

    Authors: David Alexoff, Seok Rye Choi, Karl Ploessl, Dohyun Kim, Ruiyue Zhao, Lin Zhu and Hank Kung
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:15
  38. Programmed cell death ligand 1 (PD-L1) plays a critical role in the tumor microenvironment and overexpression in several solid cancers has been reported. This was associated with a downregulation of the local ...

    Authors: Fabian Krutzek, Cornelius K. Donat and Sven Stadlbauer
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:14
  39. The gastrin-releasing peptide receptor (GRPR) has been extensively studied as a biomolecular target for peptide-based radiotheranostics. However, the lack of metabolic stability and the rapid clearance of pept...

    Authors: Panagiotis Kanellopoulos, Adam Mattsson, Ayman Abouzayed, Karim Obeid, Berthold A. Nock, Vladimir Tolmachev, Theodosia Maina and Anna Orlova
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:13
  40. Nanoparticles exhibit distinct behaviours within the body, depending on their physicochemical properties and administration routes. However, in vivo behaviour of poly(lactic-co-glycolic acid) (PLGA) nanoparticles...

    Authors: Seung Ho Baek, Eun-Ha Hwang, Gyeung Haeng Hur, Green Kim, You Jung An, Jae-Hak Park and Jung Joo Hong
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:12
  41. Automated dispensing systems (ADSs) for radiopharmaceuticals have been developed to reduce the radiation exposure of personnel, to improve the accuracy of the dispensed dose and to limit the microbiological co...

    Authors: T. T. Cao, E. A. Aalbersberg, M. M. Geluk-Jonker and J. J. M. A. Hendrikx
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:11
  42. Multidrug resistance-associated protein 1 (MRP1), an energy-dependent efflux pump, is expressed widely in various tissues and contributes to many physiological and pathophysiological processes. 6-Bromo-7-[11C]met...

    Authors: Toshimitsu Okamura, Tatsuya Kikuchi, Masanao Ogawa and Ming-Rong Zhang
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:10
  43. In the past years, there has been a notable increase in interest regarding targeted alpha therapy using Ac-225, driven by the observed promising clinical anti-tumor effects. As the production and technology ha...

    Authors: Eline L. Hooijman, Valery Radchenko, Sui Wai Ling, Mark Konijnenberg, Tessa Brabander, Stijn L. W. Koolen and Erik de Blois
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:9
  44. Overexpressed in various solid tumors, gastrin-releasing peptide receptor (GRPR) is a promising cancer imaging marker and therapeutic target. Although antagonists are preferable for the development of GRPR-tar...

    Authors: Lei Wang, Hsiou-Ting Kuo, Zhengxing Zhang, Chengcheng Zhang, Chao-Cheng Chen, Devon Chapple, Ryan Wilson, Nadine Colpo, François Bénard and Kuo-Shyan Lin
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:8
  45. The current generation of radiolabeled PSMA-targeting therapeutic agents is limited by prominent salivary gland binding, which results in dose-limiting xerostomia from radiation exposure. JB-1498 is a urea-bas...

    Authors: Steve S. Huang, Frank P. DiFilippo, Daniel J. Lindner and Warren D. Heston
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:7
  46. We aimed to develop a publicly shared computational physiologically based pharmacokinetic (PBPK) model to reliably simulate and analyze radiopharmaceutical therapies (RPTs), including probing of hot-cold ligan...

    Authors: Ali Fele-Paranj, Babak Saboury, Carlos Uribe and Arman Rahmim
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:6

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2024 9:22

  47. Triple-negative breast cancer (TNBC) is one of the most lethal malignant tumors among women, characterized by high invasiveness, high heterogeneity, and lack of specific therapeutic targets such as estrogen re...

    Authors: Yitian Wu, Tuo li, Xianzhong Zhang, Hongli Jing, Fang Li and Li Huo
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:5
  48. The 18F/19F-isotope exchange method employing P(V)-centered prosthetic groups demonstrates advantages in addressing mild one-step aqueous 18F-labeling of peptides and proteins. However, the molar activity (Am) ac...

    Authors: Xiaoqun Tang, Shengji Lv, Zhaobiao Mou, Xia Liu and Zijing Li
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:4
  49. There are only a handful of true theranostic matched pairs, and in particular the theranostic radiocopper trio 61Cu, 64Cu and 67Cu, for diagnosis and therapy respectively, is a very attractive candidate. In fact,...

    Authors: Santiago Andrés Brühlmann, Martin Walther, Klaus Kopka and Martin Kreller
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:3

EJNMMI Reports - Kindly explore our collections here

Topical Collections about latest and interesting topics in EJNMMI Radiopharmacy and Chemistry are available at: https://link.springer.com/journal/41824/collections

EANM'24 - Future Congress!

EANM'24 banner horizontal

Future Congress

37th Annual Congress of the European Association of Nuclear Medicine

October 19 – 23, 2024
Hamburg, Germany


CCH – Congress Center Hamburg
Congressplatz 1
20355 Hamburg, Germany
URL: https://www.cch.de/en/

EJNMMI Journal Family and EANM Springer Award

New Content Item

EJNMMI is part of the EJNMMI Journal Family. Highlights of our featured content and the latest developments from the EJNMMI group of journals can be found on the EJNMMI Journal Family webpage. There details about the annual EANM Springer Award are available as well.


Do you want to publish your paper open access?

Details of the OpenChoice option in EJNMMI are available in the submission guidelines.

If your institution has a Read and Publish (Springer Compact) agreement, you may publish your article open access at no cost to you. In addition, you can enjoy full access to all Springer subscription journal content.

Please check the agreement details by participating country here.